UT-WYSS-CENTER
The Wyss Center for Bio and Neuroengineering has granted a worldwide license to Blackrock Microsystems to commercialize its neural signal processing and decoding software platform for research and clinical applications. The agreement follows a long-standing collaborative relationship and represents the first of many important neurotechnology developments the Wyss Center and Blackrock Microsystems intend to advance together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005373/en/
“One limitation of neural signal processing applications is that there is no single software platform that directly works with the multiple devices collecting brain signals. Researchers and clinicians have to develop their own software to analyze the signals from a patient, which limits effectiveness and slows down the implementation of solutions to the clinic,” said David Ibanez, Ph.D., Brain Machine Interface Scientist at the Wyss Center. Ibanez has been leading the Wyss Center’s software platform development efforts over recent months.
Optimized for use with implantable, high-channel count brain-computer interfaces (BCIs), the Wyss Center’s high-performance data analysis platform, called NeuroKey, is an important building block for complete real-time neural interface research and clinical applications, including restoration of movement, communication and control of assistive devices.
The medical-grade platform is compatible with commercial hardware and sensors and can be adapted to custom-made devices. NeuroKey has the potential to accelerate BCI technology research and development for clinical deployment in the lab and at home.
“Access to enabling devices at home, would give me greater independence and freedom,” said Ian Burkhart. Known as a BCI Pioneer, Ian has an enabling neural interface developed by Blackrock Microsystems. He sustained a spinal cord injury during a diving accident in 2010. "Currently BCI devices can only be used under extreme supervision in controlled environments, however, this innovation from Blackrock Microsystems and the Wyss Center pushes research to a stage where these devices can advance into the real world.”
The partnership between the Wyss Center and Blackrock Microsystems is a strong example of the Center’s translational approach. It combines the technical talent and research and development efforts of the Center’s staff with the clinical and market knowledge of Blackrock Microsystems, who has been the leading provider of reliable invasive brain computer interface technology to researchers and BCI Pioneers (tetraplegic patients) for more than a decade.
“Blackrock Microsystems is proud to be collaborating with the Wyss Center in an effort to bring life-changing innovation and neuro technology to patients,” said Marcus Gerhardt, MPhil, MA, Blackrock Microsystem’s co-founder and CEO.
“We hope that this is the first of many joint neurotechnology developments with Blackrock Microsystems, that will have a big impact on many people’s lives,” added Wyss Center’s CEO Mary Tolikas, Ph.D., MBA.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroradiology and neurotechnology, to reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease and to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
About Blackrock Microsystems LLC
Blackrock Microsystems, based in Salt Lake City, Utah, was founded in 2008 and is the world’s leading provider of technology in the neuroscience, neural engineering, and neural prosthetics space. The company’s technology is at the core of worldwide innovations in Brain-Machine Interfaces (BMI/BCI), implantable bionic technologies and epilepsy diagnostics. Most impactful implantations of the Utah Array have been in some tetraplegic individuals from University of Pittsburgh’s Nathan Copeland, who controlled a prosthetic arm to fist bump US President Barack Obama in 2016; Ohio State University’s Ian Burkhart who is learning to control an automobile, and CalTech’s Nancy Smith who is learning to play a virtual piano. Seemingly easy tasks, all have used the Utah Array to translate their thoughts into action to restore function.
Image
Download
(20 MB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 08:00:00 CET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release
Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o
Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 00:08:00 CET | Press release
New research quantifies the massive conversion lift from optimizing native app and web experiences, providing a critical no-code path for retailers to drive profitability Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who do
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 17:30:00 CET | Press release
Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer
Pure Lithium Receives Saudi Patent for Vertically Integrated Lithium Metal Battery Technology25.11.2025 14:20:00 CET | Press release
Pure Lithium Corporation, a disruptive lithium metal battery technology company, is pleased to announce that the Kingdom of Saudi Arabia has granted the company a foundational patent titled “Vertically Integrated Pure Lithium Metal Production and Lithium Battery Production.” This broad patent covers technology that combines lithium extraction, anode production and battery manufacturing. Pure Lithium’s Brine to Battery™ is a registered trademark in the Kingdom of Saudi Arabia, planting a strong base of intellectual property in the region. “The technology is particularly relevant to Saudi Arabia because it is one of the places in the world with lithium-containing brines, and even has an abundance of vanadium, which is used in our second-generation battery,” said Founder, Chairman and CEO Emilie Bodoin. “In order to displace today’s lithium-ion battery, our vision is to create global battery hubs with closed loop supply chains, not just in the U.S., but in the many places in the world whe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
